These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 15260911)

  • 1. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
    Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
    Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.
    Liem-Moolenaar M; Rad M; Zamuner S; Cohen AF; Lemme F; Franson KL; van Gerven JM; Pich EM
    Br J Clin Pharmacol; 2011 Jun; 71(6):907-16. PubMed ID: 21223356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing drug prototypes: pharmacology replaces safety and tolerability?
    Cohen AF
    Nat Rev Drug Discov; 2010 Nov; 9(11):856-65. PubMed ID: 20847743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.
    Cohen A
    Clin Pharmacokinet; 2008; 47(6):373-81. PubMed ID: 18479172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.
    Kemme MJ; vd Post JP; Schoemaker RC; Straub M; Cohen AF; van Gerven JM
    Br J Clin Pharmacol; 2003 Jun; 55(6):518-25. PubMed ID: 12814444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects.
    de Visser SJ; van Gerven JM; Schoemaker RC; Cohen AF
    Br J Clin Pharmacol; 2001 May; 51(5):423-8. PubMed ID: 11421999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function.
    Harron DW; Hasson B; Regan M; McClelland RJ; King DJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 2():S48-54. PubMed ID: 8642806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of rilmenidine on the central nervous system and kidney].
    Fillastre JP
    Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():19-23. PubMed ID: 2517005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients.
    de Visser SJ; van der Post JP; Nanhekhan L; Schoemaker RC; Cohen AF; van Gerven JM
    Clin Pharmacol Ther; 2002 Oct; 72(4):419-28. PubMed ID: 12386644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.
    van der Post JP; de Visser SJ; Schoemaker RC; Cohen AF; van Gerven JM
    J Psychopharmacol; 2004 Jun; 18(2):221-7. PubMed ID: 15260911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current data on the pharmacology of rilmenidine].
    Montastruc JL; Macquin-Mavier I; Damase-Michel C; Dard B; Tran MA; Valet P
    Arch Mal Coeur Vaiss; 1989 Dec; 82 Spec No 5():25-9. PubMed ID: 2517006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rilmenidine and the high risk hypertensive patient.
    Laragh JH
    Ann N Y Acad Sci; 1995 Jul; 763():634-41. PubMed ID: 7677383
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.